Impilo joins the ESG Data Convergence Initiative reaffirms commitment to ESG disclosure and standardization

Impilo AB, today announced that it has joined the ESG Data Convergence Initiative, a global effort to improve ESG (Environmental, Social, and Governance) data standardization and disclosure.

The ESG Data Convergence Initiative (EDCI) is an open partnership of private equity industry stakeholders committed to streamlining the industry’s approach to collecting and reporting on ESG. It brings together more than 275 General & Limited Partners with some $26tn asset under management, and more than 2000 portfolio companies. By joining this initiative, Impilo underscores its commitment to transparency, accountability, and sustainability, and its belief that standardized ESG data is crucial for informed decision-making.

Impilo’s Managing Partner, Fredrik Strömholm comments:

“Joining the ESG Data Convergence Initiative is an important step on our sustainability journey. We believe that managing ESG factors is essential to long-term business success and that it will contribute to a more sustainable healthcare system. The disclosure of our performance is critical, and we are committed to providing investors with accurate, reliable, and comparable ESG data. By working with other leading companies and stakeholders in this initiative, we can help shape the future of ESG data reporting and improve the quality and accessibility of ESG information.”

As part of its commitment to ESG disclosure and standardization, Impilo has already taken a number of steps to enhance its ESG reporting, including requiring portfolio companies to disclose performance against the EDCI indicators as well as a number of other ESG indicators, reporting regularly to investors on portfolio companies’ performance on the Impilo Sustainability Blueprint, and by publishing an annual sustainability report. In addition, Impilo works with its portfolio companies to demonstrate how they contribute to creating health impact. Read more about how we work with promoting health impact and advancing sustainability in our annual sustainability report for 2022.

 

Contact details
Fredrik Strömholm, Managing Partner, Impilo, +46-76 115 10 65, fredrik.stromholm@impilo.se

Martin Fagerlund, COO & Partner, Impilo, +46-70 943 23 30, martin.fagerlund@impilo.se

 

About Impilo
Impilo is a Nordic investment company focused on investments in sustainable healthcare companies active in the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo strives to increase value of its investments through long-term active ownership. Impilo has a well-diversified portfolio of healthcare investments and manages c. EUR 1 billion of capital from leading Nordic and international investors.

News

Impilo’s portfolio company Decon acquires Acekare – a French-based manufacturer and distributor of mobility assistance solutions

The acquisition of Acekare marks an important step in Decon’s strategic ambition to build a leading European niche mobility platform by adding a complementary product company to its existing offering and establishing a direct presence in the French market

Read article

Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry

Impilo’s portfolio company Pelago Bioscience acquires RG Discovery, forming an integrated drug discovery partner spanning biology and chemistry

Read article

Impilo completes the acquisition of Oticon Medical

We are pleased to announce that Impilo has today completed the acquisition of Oticon Medical from Demant A/S. This marks the first investment in our recently raised Fund II.

Read article